Eylem Pınar ESER, İlknur Alkan KUŞABBİ, Abdullah DURHAN, Koray KOŞMAZ, Marlen SÜLEYMAN, Mehmet ŞENEŞ, Sema HÜCÜMENOĞLU, Mustafa Taner BOSTANCI, Yılmaz ÜNAL, Tuğba YİĞİT HASKARACA, Can ERSAK

The effect of Ankaferd blood stopper on liver damage in experimental obstructive jaundice

Background/aims: To evaluate the potential protective effects of Ankaferd blood stopper (ABS) in an experimental obstructive jaundice (OJ) model. Materials and methods: The study included 26 female rats, which were divided into 3 groups. The sham group, consisting of 10 rats, (group 1) only received solely laparotomy. In the control group, consisting of 8 rats, (group 2), ligation was applied to the biliary tract and no treatment was implemented. In the treatment group, consisting of 8 rats, (group 3), following ligation of biliary tract, 0.5 mL/day ABS was given for 10 days. Liver tissue and blood samples were taken for histopathological and biochemical examination. Results : Compared to group 2, group 3 had higher aspartate aminotransferase (AST), total oxidant status (TOS) malondialdehyde (MDA), fluorescent oxidant products (FOP), and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). In histopathological analysis, the mean scores of all histopathological parameters (fibrosis, portal inflammation, confluent necrosis, interphase activity, bile duct proliferation) have statistical significance between group 2 and group 3 (P < 005). Conclusions: ABS has promising results in the treatment of experimental OJ because of its antioxidant and antiinflammatory properties. It may be used in clinical practice after more extensive studies about the effects of ABS on OJ.Key words: Obstructive jaundice, Ankaferd blood stopper, antioxidant

PDF

___

1. Gümüs M, Tekin R, Firat U, Önder A, Kapan M et al. The effects of pomegranate on bacterial translocation in rats with obstructive jaundice. European Review for Medical and Pharmacological Sciences 2013; 17 (11): 1488-1494.
2. Kilicoglu B, Gencay C, Kismet K, Serin Kilicoglu S, Erguder I et al. The ultrastructural research of liver in experimental obstructive jaundice and effect of honey. The American Journal of Surgery 2008; 195 (2): 249-256. doi: 10.1016/j. amjsurg.2007.04.011
3. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54 (7): 1024-1033. doi: 10.1136/ gut.2004.053850
4. Onalan AK, Tuncal S, Kilicoglu S, Celepli S, Durak E et al. Effect of silymarin on oxidative stress and liver histopathology in experimental obstructive jaundice model. Acta Cirurgica Brasileira 2016; 31 (12): 801-806. doi: 10.1590/S0102- 865020160120000004
5. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Alternative Medicine Review 2010; 15 (4): 329-336.
6. Koçak E, Akbal E, Taş A, Köklü S, Karaca G et al. Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model. Saudi Journal of Gastroenterology 2013; 19 (3): 126-130. doi: 10.4103/1319-3767.111955
7. Saribas Z, Sener B, Haznedaroglu IC. Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens. Central European Journal of Medicine 2010; 5 (2): 198-202. doi: 10.2478/s11536-009-0140-4
8. Ciftci S, Keskin F, Keceli Ozcan S, Erdem MA, Cankaya B et al. In vitro antifungal activity of Ankaferd blood stopper against Candida albicans. Current Therapeutic Research 2011; 72 (3): 120-126. doi: 10.1016/j.curtheres.2011.04.003
9. Wasowicz W, Nève J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clinical Chemistry 1993; 39 (12): 2522-2526.
10. Wu T, Willett WC, Rifai N, Rimm EB. Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies. American Journal of Epidemiology 2007; 166 (5): 552-560. doi: 10.1093/aje/kwm119
11. Aller MA, Arias JL, Garcia-Dominguez J, Arias JI, Duran M et al. Experimental obstructive cholestasis: the wound-like inflammatory liver response. Fibrogenesis Tissue Repair 2008; 1 (1): 6. doi: 10.1186/1755-1536-1-6
12. Akca T, Canbaz H, Tataroglu C, Caglikulekci M, Tamer L et al. The effect of N-acetylcysteine on pulmonary lipid peroxidation and tissue damage. Journal of Surgical Research 2005; 129 (1): 38-45. doi: 10.1016/j.jss.2005.05.026
13. Copple BL, Jaeschke H, Klaassen CD. Oxidative stress and the pathogenesis of cholestasis. Seminars in Liver Disease 2010; 30 (2): 195-204. doi: 10.1055/s-0030-1253228
14. Zhang XP, Qiu FM, Wang X. Therapeutic mechanisms of single Chinese medicine herb or their extracts for extrahepatic obstructive jaundice. Chinese Journal of Integrative Medicine 2014; 20 (6): 474-480. doi:10.1007/s11655-013-1558-8
15. Bast A, Haenen GR, Doelman CJ. Oxidants and antioxidants: state of art. The American Journal of Medicine 1991; 91 (3C): 2-7. doi:10.1016/0002-9343(91)90278-6
16. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Briceño J et al. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radical Research 2004; 38 (7): 697-704. doi: 10.1080/10715760410001705131
17. Kismet K, Sabuncuoglu MZ, Kilicoglu SS, Kilicoglu B, Devrim E et al. Effect of propolis on oxidative stress and histomorphology of liver tissue in experimental obstructive jaundice. European Surgical Research 2008; 41 (2): 231-237. doi:10.1159/000136479
18. Koluman A, Akar N, Malkan U.Y, Haznedaroglu IC. Qualitative/ chemical analyses of Ankaferd hemostat and its antioxidant content in synthetic gastric fluids. BioMed Research International 2016; 2016: 8957820. doi: 10.1155/2016/8957820
19. Srinivasa V, Sundaram MS, Anusha S, Hemshekhar M, Nayaka SC et al. Novel apigenin based small molecule that targets snake venom metalloproteases. Plos One 2014; 9 (9): e106364. doi:10.1371/journal.pone.0106364
20. Inoue A, Takitani K, Koh M, Kawakami C, Kuno T et al. Induction of apoptosis by γ-tocotrienol in human cancer cell lines and leukemic blasts from patients: dependency on bid, cytochrome c, and caspase pathway. Nutrition and Cancer 2011; 63 (5): 763-770. doi: 10.1080/01635581.2011.563030
21. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T et al. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Letters 2005; 229 (2): 181-191. doi:10.1016/j. canlet.2005.06.036
22. Miyazawa T, Shibata A, Nakagawa K, and Tsuzuki T. Antiangiogenic function of tocotrienol. Asia Pacific Journal of Clinical Nutrition 2008; 17 (Suppl 1): 253-256.
23. Ling MT, Luk SU, Al-Ejeh, F and Khanna KK. Tocotrienol as a potential anticancer agent. Carcinogenesis 2012; 33 (2): 233-239. doi: 10.1093/carcin/bgr261
24. Mumcuoglu M, Akin DF Ezer U, Akar N. Ankaferd blood stopper induces apoptosis and regulates PAR1 and EPCR expression in human leukemia cells. Egyptian Journal of Medical Human Genetics 2015; 16 (1): 19-27. doi :10.1016/j.ejmhg.2014.10.001
25. Avcu F, Guner M, Misirci M, P. Elci P, Safali M et al. Evaluation of antineoplastic effects of a new hemostatic agent Ankaferd blood stopper on myeloma cell line and plasmocytoma development in Balb/c mice: results of the first in vitro and in vivo study. Blood 2014; 124 (21): 5728. doi: 10.1182/blood. V124.21.5728.5728
26. Akalin I, Okur FV, Haznedaroglu IC, Sayinalp N, Aksu S et al. Acute in vitro effects of ABS (Ankaferd Hemostat) on the lymphoid neoplastic cells (B-CLL and RAJI tumor cell lines). International Journal of Hematology and Oncology 2014; 24 (4): 253-259. doi: 10.4999/uhod.13026
27. Turhan N, Kurt M, Shorbagi A, Akdogan M, Haznedaroglu IC. Topical ankaferd blood stopper administration to bleeding gastrointestinal carcinomas decreases tumor vascularization. The American Journal of Gastroenterology 2009; 104 (11): 2874-2877. doi: 10.1038/ajg.2009.431
28. Huri E, Akgul T, Astarci M, Ustun H, C. Germiyanoglu C. S71 The effect of a novel hemostatic agent, Ankaferd Bloodstopper® (ABS), on renal tubular apoptosis in rat partial nephrectomy model. European Urology 2009; 8 (8): 631. doi: 10.1016/S1569-9056(09)74952-8
29. Mihmanli A, Ulker Z, Alpsoy L, Ezirganli S. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd blood stopper® using different assays. Human & Experimental Toxicology 2012; 31 (8): 780-787. doi:10.1177/0960327111434949
30. Isler SC, Demircan S, Cakarer S, Cebi Z, Keskin C et al. Effects of folk medicinal plant extract Ankaferd blood stopper on early bone healing. Journal of Applied Oral Science 2010; 18 (4): 409-414. doi:10.1590/s1678-77572010000400015
31. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC et al. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Critical Reviews in Oncology/Hematology 2012; 83 (1): 21-34. doi: 10.1016/j.critrevonc.2011.10.006
32. Goker H, Kilic E, Cetinkaya D. Anti-cancer activity of Ankaferd on human colon cancer (CaCo-2) in vitro. In: Haznedaroglu IC, Goker H, Ozdemir O, et al. (editors) Ankaferd: scientific perspectives and basic-clinical data. İstanbul, Turkey: Naviga Publications, 2008, p. 108.
33. Turk S, Malkan U.Y, Ghasemi M, Hocaoglu H, Mutlu D et al. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines. SAGE Open Medicine 2017; 5. doi: 10.1177/2050312116689519
34. Ghasemi M, Okay M, Malkan U.Y, Türk S, Jabbar J et al. Ankaferd hemostat affects etoposide resistance of the malignant melanoma cells. International Journal of Hematology and Oncology 2020; 30 (1): 43-53. doi: 10.4999/uhod.203965
35. Akalin C, Kuru S, Barlas AM, Kismet K, Kaplanoglu B et al. Beneficial effects of Ankaferd blood stopper on dermal wound healing: an experimental study. International Wound Journal 2014; 11 (1): 64-68. doi:10.1111/j.1742-481X.2012.01063.x
36. Kaya H, Gokdemir MT, Sogut O, Demir T, Koçarslan S. Effects of folk medicinal plant extract Ankaferd blood stopper on burn wound healing. Acta Medica Mediterranea 2013; 29 (3): 497- 502.
37. Kawada N, Seki S, Inove M, Kuroki T. Effect of antioxidants resveratrol, quercetin and N-acetlycysteine on the functions of cultured rat hepatic stellate cells and kupffer cells. Hepatology 1998; 27 (5): 1265-1274. doi: 10.1002/hep.510270512
38. Ljubuncic P, Tanne Z, Bomzon A. Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease. Gut 2000; 47 (5): 710-716. doi:10.1136/gut.47.5.710
39. El-Nekeetty AA, Mohamed SR, Hathout AS, Nassan NS, Aly SE et al. Antioxidant properties of Thyms vulgaris oil against aflatoxin - induced oxidative stress in male rats. Toxicon 2011; 57 (78): 984-991. doi:10.1016/j.toxicon.2011.03.021
40. Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira MBPP. Liquorice (Glycyrrhiza glabra): a phytochemical and pharmacological review. Phytotherapy Research 2018; 32 (12): 2323-2339. doi:10.1002/ptr.6178
41. Hasgul R, Uysal S, Haltas H, Akyol S, Yuksel Y et al. Protective effects of ankaferd blood stopper on aspirin-induced oxidative mucosal damage in a rat model of gastric injury. Toxicology and Industrial Health 2014; 30 (10): 888-895. doi:10.1177/0748233712466134
42. Akbal E, Köklü S, Astarcı HM, Koçak E, Karaca G et al. Oral high-dose ankaferd administration effects on gastrointestinal system. International Journal of Medical Sciences 2013; 10 (4): 451-456. doi:10.7150/ijms.4875